Keywords: advancis/par, pulsys, misses, ph, iii, endpoint, advancis
Advancis/Par's PULSYS misses Ph III endpoint
Article | 27 June 2005
Advancis Pharmaceutical, a firm focused on novel anti-infectives, and fellow US firm Par Pharmaceutical say that a Phase III trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
